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Intratumoral heterogeneity in non–small cell lung cancer (NSCLC) has been appreciated at the histological and
cellular levels, but the association of less differentiated pathology with poor clinical outcome is not understood at
the molecular level. Gene expression profiling of intact human tumors fails to reveal the molecular nature of
functionally distinct epithelial cell subpopulations, in particular the tumor cells that fuel tumor growth, metastasis,
and disease relapse. We generated primary serum-free cultures of NSCLC and then exposed them to conditions
known to promote differentiation: the air-liquid interface (ALI) and serum. The transcriptional network of the
primary cultures was associated with stem cells, indicating a poorly differentiated state, and worse overall survival
of NSCLC patients. Strikingly, the overexpression of RNA splicing and processing factors was a prominent feature
of the poorly differentiated cells and was also observed in clinical datasets. A genome-wide analysis of splice
isoform expression revealed many alternative splicing events that were specific to the differentiation state of the
cells, including an unexpectedly high frequency of events on chromosome 19. The poorly differentiated cells
exhibited alternative splicing in many genes associated with tumor progression, as exemplified by the preferential
expression of the short isoform of telomeric repeat-binding factor 1 (TERF1), also known as Pin2. Our findings
demonstrate the utility of the ALI method for probing the molecular mechanisms that underlie NSCLC
pathogenesis and provide novel insight into posttranscriptional mechanisms in poorly differentiated lung cancer
cells.
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Non–small cell lung cancer (NSCLC) remains the leading cause of
cancer-related deaths despite the successful development of many
therapies. Less differentiated NSCLC tumors are associated with
increased risk of death and increased risk of recurrence following
tumor resection [1]. Poorly differentiated and dedifferentiated cancer
cells can exhibit stem cell–like properties, including multipotency,
tumor-initiating capacity, and the expression of stem cell factors.
The isolation and characterization of tumor cell subpopulations by
fluorescence-activated cell sorting are commonly used to generate
gene expression profiles of more aggressive populations, but the
liabilities associated with this approach include the need for
dissociation of tissue to single cells and the use of immune-compro-
mised mice to define the tumorigenic populations [2] — not by
differentiation status, which is the basis of the clinical analyses. As a
complementary approach that circumvents both of these conditions,we characterized lung cancer cells with distinct differentiation states
by establishing primary serum-free NSCLC cultures and then
inducing differentiation by various methods.
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without the acquisition of genetic or epigenetic alterations requires
sophisticated techniques such as defined serum-free media and
three-dimensional (3D) matrices [3,4]. A relevant culture method to
study the developmental hierarchy of normal and cancerous lung cells
is the air-liquid interface (ALI), in which cells are induced to
differentiate in 3D growth by exposure to the air. The ALI method
has been used to investigate gene networks, differentiation potential,
and in vivo relevance of normal human bronchial epithelial cells
(HBECs) [5,6] and subsequently adapted to study the cellular
hierarchy of a primary NSCLC culture [7]. However, the direct
comparison of ALI to conventional methods such as serum has not
been conducted in NSCLC but would inform the relevant approaches
to characterize the gene expression and mRNA splicing profiles of the
poorly differentiated state.
The dysregulation of mRNA splicing has been implicated in
tumorigenesis and therapeutic resistance [8–10], but genome-wide
analysis of mRNA splicing has not been broadly applied to the study
of poorly differentiated cancer cells. The differential expression of
mRNA splice isoforms of various genes regulates differentiation and
pluripotency in normal tissue stem cells [11,12], but its prevalence
and functions in poorly differentiated cancer cells are not well
characterized.
We demonstrate that poorly differentiated NSCLC cells
overexpress RNA processing factors and exhibit a distinct profile
of alternatively spliced mRNAs. As a striking example, the short
isoform of the telomere factor TERF1 is enriched in the poorly
differentiated state. The clinical relevance of the ALI method for
studying NSCLC was revealed by comparison to patient datasets
and generation of gene signatures that predict survival outcomes.
These results provide insight at the molecular level into the
correlation between poorly differentiated tumor histology and worse
clinical outcome.
Materials and Methods
Serum-Free Culture of Human NSCLC Cells
Human lung tumor tissue was obtained from Asterand in
accordance with appropriate consent procedures, and cell cultures
were established on Matrigel (BD Biosciences)-coated flasks in
serum-free bronchial epithelial cell growth medium (BEGM;
Lonza) as described [7]. Matrigel was diluted in PBS to 0.4 mg/
ml, transferred to culture flasks, and allowed to solidify overnight at
room temperature before adding cells. TUM449 cell line was
generated from patient tumor sample 87449A1, an NSCLC
adenocarcinoma, and TUM110 cell line was generated from patient
sample 60110A1, an NSCLC squamous cell carcinoma.
Air-Liquid Interface Cultures
Millicell 1-μm PET hanging cell culture inserts (Millipore) lacking
Matrigel were seeded with 1.5 × 105 cells in BEGM. After 2 to 3 days,
the upper and lower chambers were rinsed with PBS, and CnT23
medium (CELLnTec) containing 50 nmol/l of retinoic acid,
1 mmol/l of CaCl2, or BEGM was added only to the lower chamber,
leaving cells exposed to the air (5% CO2 in a tissue culture incubator).
Lifted cultures were fed every other day with fresh medium. For
serum differentiation, cells were seeded in BEGM onto multiwell
plates lacking Matrigel and switched to Ham’s F-12K (Kaighn’s)
medium containing 10% fetal bovine serum (FBS).Alternative Splicing
SpliceArray™ micorarrays (Diaxonhit) contain body probes that
monitor exon bodies and are designated F, T, and B, and junction
probes that monitor exon-exon junctions are designated C, D, and E.
Preprocessing steps including robust multi-array average background
correction, quantile normalization, and mean probe summarization
were performed on the CEL files using Partek software (Partek Inc.,
St. Louis, MO). Microarray processing methods have been published
[13] and are described in Supplemental Information. Gene level
expression from SpliceArray™ was calculated as the geometric mean of
all F and T probes, wherease gene level expression from Affymetrix
platform was summarized as median of all probe sets. Correlation
analysis of gene level expression change between differentiated and
undifferentiated condition (log2ratio) was performed using Pearson
method. Event level change for each alternatively spliced event was
calculated as the ratio of geometric means between probes that target
the variant transcript to the reference transcript (B, C, D, and E).
Differential event level change between the differentiated and
undifferentiated conditions was analyzed by analysis of variance
method using Partek software (Partek Inc). Significantly altered
events are defined as those that with a fold-change ≥ 2 and false
discovery rate (FDR) ≤ 0.05 in both cultures. The RNAseq method
was not feasible in this scenario because of limited quantities of RNA.
TERF1 Reverse Transcriptase Polymerase Chain
Reaction (RT-PCR)
Short- and long-form TERF1 transcripts were detected by PCR
with splice variant specific primer sets previously developed [14].
PCRs were run on an Applied Biosystems Veriti thermocycler. PCR
products were resolved on 20% polyacrylamide gels, stained with
Sybr Green (Life Technologies), and imaged with the ChemiDoc
XRS. Band intensities were quantitated using ImageJ software.
Results
Gene Signatures of Poorly Differentiated NSCLC Cells
To extend our initial study of NSCLC at the ALI [7], we
established and maintained two additional NSCLC cultures,
TUM110 and TUM449, in serum-free BEGM and induced the
cells to differentiate in three conditions (Figure 1A). The TUM110
culture was established from a female patient diagnosed with poorly
differentiated squamous cell carcinoma of the lung (Union for
International Cancer Control stage T2N0MX), and the TUM449
culture was from a female patient diagnosed with moderately
differentiated adenocarcinoma of the lung (Union for International
Cancer Control stage T2N0MX). In one differentiation condition,
“BEGM-ALI,” the cells were exposed to the ALI in standard BEGM
medium, which is similar to the medium used for ALI cultures of
HBECs [6,15]. In another condition, “CnT23-ALI,” which was used
in the original study [7], cells were exposed to the ALI in protein-free
CnT23 medium, which contains 50 nM retinoic acid and 1 mM
CaCl2. In the third condition, “Serum,” cells were cultured in
standard tissue-culture plates submerged in medium that contains
10% FBS; this condition has long been known to induce
differentiation in HBECs [16].
Upon exposure to the ALI, the tumor cells formed a 3D
multilayered epithelium (Figure 1B), consistent with previous reports
[7,17]. ALI samples were harvested on day 16 for gene expression
profiling based on our previous studies and similarity to published
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Figure 1. Induction of differentiation of primary NSCLC cultures. (A) Serum-free NSCLC cultures were induced to differentiate at the ALI
serum-free BEGM or protein-free CnT23 media for 16 days, or by submersion in 10% serum-containing media for 4 days. (B) Relief phas
contrast images of cultures before and after differentiation. Cells exposed to the ALI formed 3D structures, whereas cells exposed t
serum remained a monolayer. Scale bar = 500 μm. Insets, high-magnification phase contrast images of cells after serum differentiatio
(C) Principal component analysis of gene expression profiles indicated the parallel nature of TUM110 and TUM449 across the fou
conditions (arrow) and highlighted the extreme effects of serum. Each dot or diamond corresponds to one sample replicate.
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expression after 8 to 10 days [4,6,7]. Cells that were exposed to serum
remained in monolayer but exhibited significant morphological
changes, such as a spindly morphology (Figure 1B). Serum samples
were harvested on day 4 because they still appear to look healthy on
that day and time courses had shown that the cells do not survive
16 days in serum. Gene expression profiles of three biological
replicates per condition were generated with the Affymetrix U133Plus
microarray platform. Principal component analysis revealed promi-
nent patterns (Figure 1C). In both cultures, the BEGM-ALI profile
was located closest to that of the poorly differentiated profile, followed
by CnT23-ALI and then serum. The arrangement of the samples
indicated that differentiation induced similar overall changes in
transcription in TUM110 and TUM449. Similar patterns were
observed by hierarchical clustering (Supplemental Figure S1A). The
analysis suggested distinct molecular outcomes of the three
conditions, especially serum; these differences were subsequently
explored by various bioinformatic analyses.in
e
o
n.
rA gene signature termed GeneSig2 was defined for each condition
as the group of probe sets with at least two-fold lower expression
(FDR ≤ 0.01) in the differentiated state in both cultures (Supple-
mental Table S1). Interestingly, each GeneSig2 contained several
genes that encode RNA processing factors; subsequent analysis
demonstrated the highly significant enrichment of these factors in
the poorly differentiated state (see below). We compared each
GeneSig2 with clinical patient-matched gene expression and
survival data. Patient samples from the NSCLC Directors’
Challenge [18] were ordered according to their expression of each
GeneSig2, and the survival data of the patients in the top and
bottom quartiles were subjected to Kaplan-Meier analysis. High
expression of the genes in GeneSig2 from each differentiation
condition was associated with worse overall survival (Figure 2A).
This result indicated that our approach could provide relevant
molecular insights into the histological observation that less
differentiated NSCLC tumors are associated with increased risk of
death [1].
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Figure 2. Gene signatures of the poorly differentiated state are associated with shorter survival in NSCLC. (A) The gene signature
Genesig2 was defined as the group of probe sets with at least two-fold higher expression (FDR ≤ 0.01) in the poorly differentiated state in
both cultures. Patient samples were ordered by median expression of the genes in GeneSig2, and survival data for patients in the top
quartile (“High”; 90 patients) and bottom quartile (“Low”; 90 patients) were subjected to Kaplan-Meier analysis. Log-rank test P value and
Cox proportional hazards (COXPH) ratio (HRatio) was calculated using R survival package. (B) Comparison of the gene signatures from
three conditions. Changes (fold-change between differentiated state and undifferentiated state) in gene expression were relatively
consistent across tumor cultures and conditions. However, in TUM449, approximately one fourth of genes in FBS GeneSig2 changed in
the opposite direction in both ALI conditions.
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(HRatio), whereas the serum signature yielded the weakest values
(BEGM: 3.27; Cnt23: 2.92; Serum: 2.5; Figure 2A) despite the fact
that the serum signature contained more than twice as many probe
sets as the other signatures. Six probes defined the intersection of
the three GeneSig2 sets (Supplemental Figure S1B), and strikingly,
this small gene set was correlated with worse overall survival (Hazard
Ratio [HRatio] = 2.02, P = .0023). Similarly, significant differences
in patient survival based on Genesig2 were also observed when the
entire patient cohort was bisected into top and bottom halves
(BEGM: P = 2.84E-05, HRatio = 1.96; Cnt23: P = .000237,
HRatio = 1.8; Serum: P = .000486, HRatio = 1.75).
However, there were also significant differences among the GeneSig2
from the three conditions. The changes in gene expression were generally
consistent across tumor cultures and conditions; most genes exhibited
changes that trended in the same direction even if the changes did not
achieve the thresholds used to generate GeneSig2 (Figure 2B). Interest-
ingly, in TUM449, approximately 25% of the probe sets in the serum
signature changed in opposite directions in serum versus both ALI
conditions. Overall, the GeneSig2 analysis demonstrated the clinical
relevance of the experimental approach to characterize the undifferentiated
state of NSCLC at the molecular level. Although clinical relevance wasdemonstrated for all three differentiation conditions, the results indicated
certain molecular consequences of both ALI and serum, which were
followed up in additional experiments below.
The converse set of gene signatures—genes with higher expression in
the differentiated state—did not exhibit any correlation with patient
survival data and thus was not pursued. This observation could be due to
the heterogeneity of differentiation as opposed to the relatively few
deviations within the poorly differentiated serum-free culture. Additional
gene signatures were generated that were comprised of genes that
increased or decreased during differentiation; patient cohorts that were
clustered by these compound gene signatures exhibited a significant
survival difference (e.g. log rank P value .013 for BEGM-ALI), but the
results were not as robust as those fromGeneSig2. Together, these results
demonstrate that the signatures defined by genes overexpressed in the
poorly differentiated state (GeneSig2) exhibited the most clinical
relevance and overall robustness.
Overexpression of mRNA Processing Factors in Poorly
Differentiated Cells
Additional bioinformatic analyses were performed with the full
gene expression profiles and thus were independent of GeneSig2.
Gene Set Enrichment Analysis (GSEA; Broad Institute) demonstrated
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significantly enriched for gene sets of poor clinical prognosis
(Figure 3A), most notably one from the Directors’ Challenge [18]
which is the same dataset used above in the independent GeneSig2
analysis. In addition, the identification of stem cell factors demonstrates
that the poorly differentiated state of the culture was associated with
metastasis factors (Figure 3A, Supplemental Figure S2A), which is
consistent with a large body of data that supports the links between
metastatic stem cells and poor survival [19,20]. Notably, the gene
expression profiles in the poorly differentiated state were enriched for at
least five gene sets containing targets of the Myc oncogene
(Supplemental Figure S2A).
Strikingly, GSEA identified many RNA processing signatures
that were enriched in the poorly differentiated state (Figure 3A).
Specifically, the signatures converged on posttranscriptionalCategory Gene Set  (enriched in undiffer
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Figure 3. GSEA of genes that are overexpressed in the undifferentiate
significance (FDR ≤ 0.01); yellow denotes moderate significance (0.0
sets are shown in Supplemental Figure S2.modification, especially mRNA splicing. Notably, there were
not many significant differences in the expression of ribosomal
protein genes and transcription factors in the poorly differentiated
versus differentiated states (Supplemental Figure S3). Thus, these
results likely reflected the overexpression of these factors
independent of any differences in total RNA synthesis or
metabolism.
Conversely, GSEA of the profiles from the differentiated state
identified gene sets associated with better patient survival and
downregulation in stem cells and metastasis (Figure 3B, Supple-
mental Figure S2B). Differentiation in serum but not ALI was
enriched for apoptosis and cell death pathways (Figure 3B), which
represented a striking contrast between the serum and ALI. The
serum condition also yielded weaker statistics or lack of significance
for several gene sets that were enriched in the ALI conditions.entiated) BEGM CnT23 Serum
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differentiated cells was independently revealed by Ingenuity Pathway
Analysis (IPA). The two pathways that were uniquely enriched in the
undifferentiated state were RNA posttranscriptional modification and
RNA trafficking (Figure 4A). Notably, these pathways were enriched only
in the ALI condition, not in serum. The pathways uniquely enriched in
the differentiated state were protein degradation, free radical scavenging,
and antigen presentation (Supplemental Figure S4).
An examination of individual genes in these pathways
demonstrated higher expression of RNA processing factors in theUndiff. BEGM Cn
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genes that changed in both cultures by at least 1.5-fold with FDR ≤
enrichment of these pathways. (B) Gene expression of mRNA splicing
corresponding P values are provided in Supplemental Table S2. Th
described in Methods.poorly differentiated state on the microarrays (Figure 4B,
Supplemental Table S2). In many cases, the change in expression
was more pronounced in ALI than in serum, which likely explains
why the IPA pathways were enriched only in ALI.
Splicing Factor Gene Alterations and Overexpression in NSCLC
Given these results, we hypothesized that mRNA processing factors
could be dysregulated across NSCLC. The expression of the genes in
IPA’s RNA posttranscriptional modification pathway was queried in
The Cancer Genome Atlas (TCGA). Indeed, almost all of the factorsT23 Serum
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with normal tissue; the results were observed in both squamous cell
carcinoma and adenocarcinoma (Figure 5).
To assess genetic alterations in these factors, TCGA was queried
with cBioPortal [21] for the same panel of genes. Genomic alterations
were observed in 71% (351/493) of squamous cell carcinoma cases
and 37% (206/563) of adenocarcinoma cases (Supplemental Figure
S5, A and B). Most of these alterations were copy number gain,
defined as at least 2.8 copies, and some were mutations; very few of
the alterations were copy number loss. The high frequency (58%) of
TRA2B copy number gain in squamous cell carcinoma accounted for
most of the difference in alteration frequencies between the subtypes.
The TRA2B amplification was not focal. Notably, the mRNA
expression level of TRA2B was highly correlated with copy number
(Pearson r = 0.75; Supplemental Figure S5C).
Alternative Splicing in Poorly Differentiated NSCLC Cells
Based on the above observations, we hypothesized that poorly
differentiated NSCLC cells might exhibit a distinct alternative
splicing profile from their differentiated counterparts. The SpliceAr-
ray™ platform enables the measurement of 281,209 splicing events,NSCLC  squamous cell carcinoma
NSCLC adenocarcinomaB
A
Figure 5. Upregulation of RNA processing factors in NSCLC
primary tumors. (A) mRNA expression levels of splicing factors in
NSCLC squamous cell carcinomas, expressed as a ratio of
expression in tumor (T) to normal tissue (N). TCGA RNAseq data
were analyzed with DESeq R package as described in the
supplement. (B) mRNA expression levels of splicing factors in
NSCLC adenocarcinomas, expressed as a ratio of expression in
tumor (T) to normal tissue (N).both documented and theoretical, and has identified novel alternative
splice isoforms in several studies [22,23]. The coordinated measure-
ment of many probes at each event provides an internal control and
allows for normalization. To generate a global alternative splicing
profile, mRNA samples from TUM110 and TUM449 in the poorly
differentiated and BEGM-ALI states (three biological replicates per
condition) were evaluated on the SpliceArray™; the BEGM-ALI
condition was chosen because it produced the most robust results in the
above analyses. Importantly, gene expression changes (measured indepen-
dently of alternative splicing events) were highly correlated on the
SpliceArray™ and Affymetrix platforms, with Pearson r values of 0.798 and
0.772 in TUM110 and TUM449, respectively (Supplemental Figure S6).
We identified 264 alternative splice events within 137 unique
genes that changed significantly between poorly differentiated and
differentiated cells in both TUM110 and TUM449 (Table 1;
Supplemental Table S3). Most of the events with significant changes
(67%) were classified as exon skipping. A total of 86.7% of the
events mapped to the coding sequence, which represented a
significant enrichment over the corresponding proportion of events
on SpliceArray (81%; P = .03 by the Fisher exact test). The
remainder mapped to the 5′ or 3′ untranslated region (Supplemen-
tal Table S4).
Global analysis of the alternative splicing events that changed
between poorly differentiated and differentiated cells revealed an
unexpectedly high proportion on chromosome 19, as normalized to
the SpliceArray events per chromosome and thus independent of gene
density (Figure 6A; P b .0001, chi-square goodness-of-fit test). The
chromosome 19 genes with splicing event changes were highly enriched
within ontology categories of extracellular factors (P = 1.7E-11), many
of which have been implicated in tumorigenesis, such as CEACAM1,
GDF15, ICAM1, C3, andMUC16 and the kallikrein-related peptidases
KLK6, KLK7, KLK8, and KLK10.
In addition, among the 137 genes were factors that have been
associated with NSCLC (e.g., ANLN, C3, CLDN4, CRYAB, EIF4A2,
ELF3, S100P, SAA, SOD2), factors with documented function in
undifferentiated cells (e.g., ALDH3A1, CEACAM3, CEACAM5,
DNMT1, GTF2I, ICAM1, L1CAM, TERF1, TOP2A), and factors
that mediate interactions with the tumor microenvironment (e.g.,Table 1. Overview of Alternatively Spliced Events That Depended on the Differentiation State
Event Type Number
of Events
Number
of Genes
Selected Examples ‡
Alternative splice acceptor 14 (5.3%) 13 ANLN, C3, DLG7, GPX3,
PRC1, SLITRK6
Alternative splice donor 14 (5.3%) 14 C3, EIF4A2, INSIG1, S100P, SAA1,
SOD2, TLR2
Exon skipped 177 (67%) 92 ALDH3A1, ANLN, C3, CEACAM5,
DDX58, DLG7, DNMT1, DPP4, ELF3,
ICAM1, IL8, IL32, L1CAM, MUC1,
MUC16, TERF1 †, TOP2A
Intron retention 3 (1.1%) 3 MUC20, CCL2
Novel exon 43 (16.3%) 35 CEACAM3, CRYAB, DNER, EIF4A2,
GPX3, GTF2I, MUC1, SAA1,
SAA2, SFRS3
Novel intron 13 (4.9%) 10 CLDN4, DDX39, GDF15, HMMR, IL32
Total 264 (100%) 137
The total number of genes is less than the sum of the number of genes from different categories because
same genes can belong to different categories.
† For TERF1 isoforms, fold-change in the isoforms between the two conditions was 4.26 (FDR = 0.024)
in TUM110 and 3.92 (FDR = 0.067) in TUM449.
‡ The full list of genes and details on each alternative splice event is provided in Supplemental Table S3.
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Figure 6. Alternative splicing in poorly differentiated NSCLC cells. (A) Chromosomal distribution of splicing events that changed between
undifferentiated and differentiated cells, normalized by the total number of SpliceArray events on each chromosome. The enrichment on
chromosome 19 was highly significant (P b .0001, chi-square goodness-of-fit test). nd, event not mapped. (B) Schematic representation
of TERF1 alternatively spliced isoforms and the SpliceArray probes (labeled B, C, D, E, F, T). (C) Differential splicing of TERF1 isoforms
detected by Splicearray in TUM110 and TUM449. (D) Polyacrylamide gel electrophoresis was used to visualize RT-PCR products amplified
by primer pairs specific to the short and long isoforms of TERF1. (E) Quantitative image analysis of TERF1 RT-PCR products normalized
to GAPDH.
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identified for each of these genes is provided in Table 1.
As a notable example of affected genes, the analysis revealed the
alternative splicing of TERF1, a gene that encodes a telomeric protein
and has two characterized splice isoforms [24–26]. Higher expression
of the short form was observed in the poorly differentiated state in
both cultures; expression relative to the differentiated state was4.26-fold (FDR = 0.024) in TUM110 and 3.92-fold (FDR = 0.067)
in TUM449 (Figure 6, B and C). TERF1 was selected for
confirmation of the SpliceArray data by RT-PCR because of prior
characterization of its two isoforms, the documented function of
TERF1 in stem cells [27], and the association between telomeres and
tumorigenesis [28,29]. We performed RT-PCR with two probe sets:
one that specifically amplifies the short form and the other that
Translational Oncology Vol. 9, No. 2, 2016 mRNA Processing in Poorly Differentiated NSCLC Geles et al. 97specifically amplifies the long form. The results were consistent with
the SpliceArray data (Figure 6, C–E). In fact, a subtle distinction was
observed in both array and RT-PCR: the short form was upregulated
in the poorly differentiated cells in both cultures; the long form was
upregulated in the differentiated cells in TUM110 but unchanged
during differentiation in TUM449. These results demonstrate that
the alternative splicing of TERF1 depends on the differentiation state
of NSCLC cells.
Discussion
The novel strategy employed in this study to characterize the
differentiation hierarchy in NSCLC revealed the upregulation of
RNA processing factors and a distinct mRNA splicing profile in
poorly differentiated cells, including the preferential expression of
the short form of TERF1. Our strategy circumvents specific
liabilities of other methods such as cell sorting and intact tissue
analysis and thus is complementary to such approaches. Our
analysis of samples that represent the two major subtypes of NSCLC
suggests that the results may apply broadly to NSCLC. Indeed, the
overexpression of RNA processing factors that we identified in this
study was also observed in the larger datasets that represent hundreds of
human NSCLC samples.
ALI Method to Study NSCLC
Inducing differentiation of stem cells by exposure to serum is a
common method [3], but our results indicate that the ALI method
constitutes a cleaner, more precise technique in NSCLC. As
appreciated previously, the 3D structures formed by cells at the
ALI resemble solid tissues more than the spindly low-density cultures
of cells exposed to serum.
Consistent with the morphological observations, three indepen-
dent lines of analysis demonstrated the greater precision and relevance
of the ALI method, in particular BEGM-ALI. First, the BEGM-ALI
gene signature showed the strongest HRatios when compared with
clinical datasets, whereas the serum signature had the weakest values
despite being comprised of a larger number of genes. Second, GSEA
revealed that BEGM-ALI exhibited the strongest enrichment of
clinical and stem cell gene signatures, whereas, in contrast, serum was
the only condition to enrich for cell death. Third, the enrichment of
RNA trafficking and RNA posttranscriptional modification in poorly
differentiated cells was observed to a significant degree for
BEGM-ALI and CnT23-ALI but not serum.
Although the ALI technique requires more time and expense and
has lower throughput relative to serum, our analysis demonstrates its
greater precision and clinical relevance. In serum differentiation, the
more extreme changes in gene expression coupled with less statistical
enrichments suggest that the method is prone to generate a substantial
amount of false positives, as well as the induction of cell death. Our
results also provide an explanation for the emergence in conventional
serum-cultured cancer cell lines of grossly altered states that do not
reflect the primary tumors [3].
Distinct mRNA Splicing Profile in Poorly Differentiated NSCLC
Analysis of the primary NSCLC cells cultured at the ALI revealed
the overexpression of mRNA processing and splicing factors in the
poorly differentiated state. The finding was based on the gene
expression changes common to TUM110 and TUM449 and was
identified by two independent analyses: GSEA and IPA. Because
there were no differences in the overall expression levels oftranscription factors or ribosomal protein genes, the finding suggested
that mRNA was being processed differently and/or more efficiently in
the less differentiated cells. Consistent with our findings, analysis of
mouse embryonic stem cell–like gene expression modules compared
with those from differentiated cells revealed the upregulation of RNA
processing factors [30]. Notably, the upregulation of mRNA
processing and splicing factors was not observed in the poorly
differentiated state of normal HBECs [6], which indicates that the
dysregulation of these factors may distinguish cancerous from normal
lung cells. Interestingly, we also identified the enrichment of Myc
signatures in the poorly differentiated cells, and one mechanism of
Myc action is to stimulate mRNA capping which in turn promotes
downstream RNA processing and translation [31].
Based on the specific enrichment of RNA processing factors in the
poorly differentiated cells, we hypothesized that a distinct mRNA
splicing profile would be evident and might promote certain
phenotypes. Indeed, we identified 264 splice events within 137
genes that differed significantly in the poorly differentiated cells of
both TUM110 and TUM449. Although alternative splice isoforms
and mutations in splicing factors have been observed widely in cancer,
our results provide evidence that alternative splicing might be
exploited differently by cancer cells within the same tumor, for
example, depending on their differentiation state. We speculate that
the disproportionately high frequency of alternative splicing events on
chromosome 19 may be connected to the high gene density on the
chromosome which could result in especially open or poised
chromatin structure and accessibility to splicing factors in the poorly
differentiated cells. These results are consistent with many other
associations between chromosome 19 and NSCLC [32].
Poorly differentiated tumor cells likely employ some of the mechanisms
that maintain normal stem cells, and the alternative splicing ofTERF1may
affect lifespan or unique DNA maintenance functions; some cell cycle
checkpoints are distinct in stem cells versus nonstem cells [33,34]. In this
respect, it is intriguing that the short isoform does not contain the serine
residue that is phosphorylated by Aurora-A kinase and known to promote
mitotic defects [35]. In addition, it is possible that the alternative splicing of
TERF1 affects its gene product’s interaction with DNA, proteins in the
shelterin complex, or proteins that modify TERF1 such as tankyrase and
F-box protein FBX4. Future studieswill be needed to explore the functional
consequences of differentiation state-dependent splicing of TERF1 to
validate their potential roles in telomere biology and tumorigenesis.
Alternative splicing events in TERF1 and other genes that are specific to
tumors and/or undifferentiated tumor cells may offer novel targets for
therapeutic intervention with less toxicity than general splicing inhibitors.
Additional downstream effects of the overexpression of RNA
processing factors may help maintain poorly differentiated cells. For
instance, mRNA transcripts might be processed more efficiently,
which may also be coupled to more efficient packaging and export to
the cytoplasm [36,37]. The faster production of translation-ready
mRNAs could enable the cell to respond more rapidly to
microenvironmental cues that regulate cell growth and differentia-
tion. Separately but not exclusively, the overexpression of RNA
splicing factors could provide a buffer against stochastic splicing
events [38] that could have unpredictable but profound consequences
in stem and progenitor cells. In the ALI model and in general,
differentiated cells proliferate more slowly than the poorly differen-
tiated cells, and it will be important to distinguish alternative splicing
as a function of proliferation versus other aspects of differentiation.
98 mRNA Processing in Poorly Differentiated NSCLC Geles et al. Translational Oncology Vol. 9, No. 2, 2016Conclusion
This study has introduced a novel strategy for the characterization of
poorly differentiated NSCLC cells and has provided insights into
their transcriptional and posttranscriptional regulation as they relate
to lung cancer pathology and clinical outcomes.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2016.01.006.
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